Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Medical Safety of Ivermectin
Descotes, J., ImmunoSafe Consultance (Preprint)
Descotes, Medical Safety of Ivermectin, , J., ImmunoSafe Consultance (Preprint)
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Safety analysis of >350 articles showing that ivermectin has an excellent safety profile. The author notes that "no severe adverse event has been reported in dozens of completed or ongoing studies involving thousands of participants worldwide to evaluate the efficacy of ivermectin against COVID-19".
Descotes et al., 5 Mar 2021, preprint, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Jacques Descotes MD, PharmD, PhD Professor Emeritus, Claude Bernard University of Lyon Fellow, US Academy of Toxicological Sciences Eurotox Registered Toxicologist IMMUNOSAFE CONSULTANCE 120 Chemin des Bouleaux 38480 Saint Jean d’Avelanne, France Tel. +33 (0)616 96 35 97 E-mail = descotes@me.com EXPERT REVIEW REPORT MEDICAL SAFETY OF IVERMECTIN As per the request of MedinCell SA (France), I the undersigned certify to have perused the publicly available information relevant to conduct an extensive analysis of ivermectin safety in human beings. The aim of the present review is to propose an independent, evaluative judgement of this information which includes original scientific publications and literature reviews, case reports, and any other source provided it can be undisputedly tracked down and freely accessed. The author personally collected and reviewed all the cited information from the beginning of September 2020 to the end of February 2021. Table of Contents I. II. III. IV. Executive summary ........................................................................................................ 2 Introduction ..................................................................................................................... 5 Summary of main nonclinical toxicity findings ................................................................ 9 Human adverse events and ivermectin exposure......................................................... 19 • Adverse events in clinical trials and following medical prescription of ivermectin .... 19 • Acute poisonings and accidental overdoses ............................................................ 24 V. Risk factors .................................................................................................................. 26 • Clinical safety of ivermectin in infants and children ................................................ 26 • Clinical safety of ivermectin in pregnant and breast-feeding women ...................... 26 • Clinical safety of ivermectin in the elderly ............................................................... 27 • Comorbidities ........................................................................................................... 27 • Drug associations .................................................................................................... 29 VI. Discussion ................................................................................................................... 31 VII. Conclusion .................................................................................................................... 33 VIII. References .................................................................................................................. 34 IX. Author's resume ........................................................................................................... 45 I. EXECUTIVE SUMMARY Ivermectin was first approved as a human medicine in 1987. In addition to 40 years of extensive use as a veterinary medicine, it has been prescribed to hundreds of millions of human beings worldwide to prevent or treat a variety of parasitic diseases. Recently, the anti-SARS-cov-2 activity of ivermectin became the focus of numerous experimental studies and clinical trials, the results and interpretation of which generated a vigorous and still ongoing debate to establish how effective ivermectin is or could be against COVID-19. Drug approvals by regulatory..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit